375 related articles for article (PubMed ID: 30496606)
1. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
4. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.
Palmisano B; Spica E; Remoli C; Labella R; Di Filippo A; Donsante S; Bini F; Raimondo D; Marinozzi F; Boyde A; Robey P; Corsi A; Riminucci M
J Bone Miner Res; 2019 Dec; 34(12):2171-2182. PubMed ID: 31295366
[TBL] [Abstract][Full Text] [Related]
5. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
6. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.
Lee SK; Lorenzo JA
Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442
[TBL] [Abstract][Full Text] [Related]
7. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
10. [RANKL and OPG expression in bone marrow-derived mesenchymal stem cells of ovariectomied promotes osteoclast development and enhances its function].
Shao B; Yu Y; Fu X; Xue H; Qi M; Shuai Y; Zhou Z; Jin Y; Yang D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Dec; 29(12):1262-6. PubMed ID: 24321069
[TBL] [Abstract][Full Text] [Related]
11. A CREB1-miR-181a-5p loop regulates the pathophysiologic features of bone marrow stromal cells in fibrous dysplasia of bone.
Fu Y; Xin Z; Ling Z; Xie H; Xiao T; Shen X; Lin J; Xu L; Jiang H
Mol Med; 2021 Jul; 27(1):81. PubMed ID: 34294046
[TBL] [Abstract][Full Text] [Related]
12. The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas.
Tekkesin MS; Mutlu S; Olgac V
Head Neck Pathol; 2011 Sep; 5(3):248-53. PubMed ID: 21643971
[TBL] [Abstract][Full Text] [Related]
13. Expression of an active Gα
Zhao X; Deng P; Iglesias-Bartolome R; Amornphimoltham P; Steffen DJ; Jin Y; Molinolo AA; de Castro LF; Ovejero D; Yuan Q; Chen Q; Han X; Bai D; Taylor SS; Yang Y; Collins MT; Gutkind JS
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E428-E437. PubMed ID: 29282319
[TBL] [Abstract][Full Text] [Related]
14. [Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
Wang J; Gao H; Wang K; Li W; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Jul; 23(7):777-80. PubMed ID: 19662974
[TBL] [Abstract][Full Text] [Related]
15. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
16. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
17. Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling.
Jiang Y; Zhang Y; Chen W; Liu C; Li X; Sun D; Liu Z; Xu Y; Mao X; Guo Q; Lin N
J Transl Med; 2014 Nov; 12():334. PubMed ID: 25471933
[TBL] [Abstract][Full Text] [Related]
18. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
20. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
